EP
RAPP icon

Essential Partners’s Rapport Therapeutics RAPP Stock Holding History

Essential Partners’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.34K Hold
40
– – ﹤0.01% 2074
2026
Q2 		$1.67K Hold
40
– – ﹤0.01% 2048
2026
Q1 		$1.25K Hold
40
– – ﹤0.01% 2172
2025
Q4 		$1.21K Hold
40
– – ﹤0.01% 1970
2025
Q3 		$1.19K Buy
40
+9
+29% +$161 ﹤0.01% 1967
2025
Q2 		$352 Buy
+31
New +$329 ﹤0.01% 1796

Other funds holding RAPP

CPW
Catalyst Private Wealth San Mateo, California $239M AUM 21.76% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners's RAPP Position: Q3 2026 in Review

Essential Partners held its Rapport Therapeutics (RAPP) position steady in Q3 2026 at 40 shares worth $1.34K. The position accounts for ﹤0.01% of the portfolio, ranked #2074.

Essential Partners first reported a position in RAPP in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.67K in Q2 2026. 8 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Essential Partners held 40 shares of Rapport Therapeutics worth $1.34K as of Q3 2026.
  • Essential Partners left its Rapport Therapeutics share count unchanged in Q3 2026.
  • Rapport Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2074 holding.
  • Essential Partners first reported a position in Rapport Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Rapport Therapeutics position peaked at $1.67K in Q2 2026.
  • 8 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.